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Genome-wide association study of clinical 
parameters in immunoglobulin light chain 
amyloidosis in three patient cohorts
Immunoglobulin light chain (AL) amyloidosis is a pro-
gressive plasma cell dyscrasia which is characterized by
the deposition of amyloid fibers derived from
immunoglobulin light chain or their fragments systemi-
cally in many organs.1 The characteristics of amyloids
relate to disease severity and sequelae, including the tar-
get organs where amyloids accumulate, such as the heart,
kidney, liver, gut and peripheral nerves. Heart failure is
usually the critical life-threatening condition; the median
survival time may range from months to some years.1 We
have recently characterized ten putative genetic risk loci
(at a significance level of <10-5) for AL amyloidosis using
a genome-wide association study (GWAS) approach on a
total of 1229 German, UK and Italian patients.2 In the
study herein we carried out a systematic GWAS-based
association study on clinical data, including the affected
organs and the isotype of serum immunoglobulins (Ig).
We hypothesized that clinical profiles may be able to
define distinct molecular subtypes.
AL amyloidosis and multiple myeloma (MM) patient
populations are described in Table 1; more details can be
found in the study by da Silva Filho and colleagues.2 A
total of nine clinical profiles were selected based on
patient numbers, amyloid organ involvement (heart, kid-
ney, heart + kidney and liver, irrespective of whether
other organs were involved) and Ig profiles (intact IgG
with l or k, l any, k any, l/k light chain only (LCO), and
l LCO). Baseline assessments and procedures included
physical examination, amyloid organ involvement and
standard laboratory values in addition to serum mono-
clonal (M)-protein, free light chains, N-terminal pro b-
type natriuretic peptide (NT-proBNP) and  cardiac tro-
ponin T  (cTNT)/ high-sensitive  (hs)TNT analyses.
Organ involvement was uniformly assessed according to
the consensus criteria agreed on by the three centers
involved.3 The collection of patient samples and associat-
ed clinical information was approved by the relevant eth-
ical review boards in accordance with the tenets of the
Declaration of Helsinki.
Analysis of the GWAS data was performed using
imputed data as described.2 Single-nucleotide polymor-
phisms (SNPs) possessing a minor allele frequency (MAF)
of <1% were excluded. Associations based on imputed
SNPs alone were not considered. The association test
between SNPs and AL amyloidosis was performed in
SNPTEST v2.5. The three data sets were combined in
meta-analysis and heterogeneity was assessed by the I2
statistic (interpreted as low <0.25, moderate 0.50 and
high >0.75). For genome-wide significance, a limit of
P<5x10-8 was used. Details of the bioinformatic analyses
can be  found in the study conducted by da Silva Filho et
al.2 and in the Online Supplementary Material. Z-scores
were calculated for SNPs as log odds ratio (OR) divided
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Table 1. Number of AL amyloidosis and multiple myeloma patients according to clinical profiles.
Clinical profiles German British Italian Joined- Age median Sex-ratiob
cohort cohort cohort cohort (range) 
in yearsa
Overall AL amyloidosis 562 410 257 1129 64 (30-87) 1.37
Ig profiles
IgGc 194 157 96 447 66 (30-87) 1.19
IgGl  160 116 69 345 66 (30-87) 1.16
IgGk 34 24 27 85 66 (40-85) 1.30
l any 438 304 188 930 64 (30-87) 1.38
k any 122 74 69 265 65 (38-87) 1.28
l/k  LCO 312 96 127 535 62 (37-84) 1.49
l LCO 231 84 89 404 62 (37-84) 1.59
Missing data for Ig types 1 82 - 83 - -
Missing data for LC types 1 32 - 33 - -
Organ profiles 
Kidney 358 320 166 844 64 (30-87) 1.30
Heart 396 239 200 835 64 (34 -87) 1.44
Heart+Kidney 180 140 106 426 63 (38-87) 1.39
Liver 105 57 32 194 63 (34-87) 1.49
Missing data for organs - 18 - 18 - -
Overall  multiple myeloma 1508 2282 - 3790 63 (27-89) 1.41
Ig profiles
IgG MM 748 - - - 57 (30-72) 1.44
IgG l  MM 200 - - - 58 (33-72) 1.17
IgG k MM 548 - - - 57 (30 -72) 1.55
aMedian age of the joined-cohort. bSex-ratio is calculated as male:female ratio for the joined cohort. cIntact IgG with l or k was counted as one profile even if they are
shown separately in the Online Supplementary Tables S1-S4. AL: immunoglobulin light chain; Ig; immunoglobulin;  LC: light chain;  LCO: light chain only;  MM: multiple myelo-
ma.
by standard error.4 Long-range promoter contacts were
probed by high-resolution capture Hi-C in GM12878
cells.5
We selected nine clinical profiles for a specific analysis
of GWAS data (Table 1). We carried out a systematic
association analysis of each of the clinical profiles against
controls in each of the three cohorts. Manhattan plots are
shown for joint analysis in four clinical profiles with
genome-wide significant associations (Figure 1). 
Among Ig profiles, the l/k LCO and the l LCO profiles
showed a strong association with SNP rs9344 (Figure 1A,
Online Supplementary Table S1). The OR for rs9344 in the
l/k LCO profile was 1.62 (P=1.99x10-12), and in the l
LCO profile  the OR was 1.70 (P=1.29x10-11). The weak-
est association was noted for the IgG profile (OR=1.20,
P=9.69x10-3), with non-overlapping 95% confidence
intervals (CIs) to the LCO profiles. For the IgG profile,
rs10507419 reached genome-wide significance with an
OR of 1.49 and P-value of 5.63x10-8 (Figure 1B). The two
isotypes, IgG l and IgG k, showed similar ORs (1.57 and
1.51, respectively), while IgG l reached  the genome-
wide significance of 2.90x10-8 (Online Supplementary Table
S2). The ORs of profiles l/k LCO (0.90), λ LCO (0.91),
liver (0.98) and k any (1.00) differed significantly (non-
overlapping 95% CIs) from the IgG profile. Genome-
wide significant association was found for SNP
rs6752376 in the heart + kidney profile (OR 1.54,
P=2.88x10-8) (Figure 1C, Online Supplementary Table S3).
The liver profile rs7820212 reached genome-wide signif-
icance even with a small patient number (n=194) (OR
1.86, P=1.86x10-8) (Figure 1D, Online Supplementary Table
S4). 
Z-scores are plotted for the four SNPs in the nine clin-
ical profiles (including overall AL amyloidosis and MM)
in the Online Supplementary Figure S1, which is based on
the data expressed in the Online Supplementary Tables S1-
S4. Online Supplementary Figure S1 illustrates the high
scores of the lead SNPs, and exemplifies the dichotomy
for rs9344 and rs10507419 in the LCO and IgG profiles.   
Regional plots of association are shown in Figure 2 for
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Figure 1. Manhattan plots of association analysis for AL amyloidosis clinical profiles with genome-wide significant results. (A) l/k LCO profile; (B) IgG profile;
C) heart + kidney profile; D) liver profile. The x-axis shows the chromosomal position and the y-axis is the significance (–log10 P; 2-tailed) of association derived
by logistic regression. The red line shows the genome-wide significance level (5x10−8) and the blue line shows suggestive significance level (1x10-5). The signif-
icant/top SNPs are labeled. In the liver profile a genome-wide significant association, based on imputed SNPs, was noted in chromosome 11 but it had a MAF





the genome-wide significant SNPs in four clinical pro-
files. For the l/k LCO profile, rs9344 on chromosome
11q13.3 maps to a splice site in the cyclin D1 gene, as
demonstrated previously (Figure 2A).2 For the IgG profile,
SNP rs10507419 on chromosome 13q13.2 maps within
the LINC00457 gene of unknown function and resides
330 kb 5’ of NBEA (Figure 2B). Promoter capture Hi-C
data is lacking for rs10507419, however, data are avail-
able for the linked SNPs rs9529347 and rs619472921
(r2=1.00), showing interaction within the NBEA gene pro-
moter (Online Supplementary Figure S2). The yellow line
links the SNPs with the promoter, P=10-10.
The heart + kidney profile risk SNP rs6752376 on chro-
mosome 2p25.2 is located between two RNA genes, 63
kb from LINC01247 and 9.9 kb 3’ of ACO17053.1 (data
not shown). Liver profile SNP rs7820212 on chromosome
8q11.23 maps 28kb 3' of FAM150A. Promoter capture Hi-
C data are lacking for rs7820212, but data are available
for the linked SNP rs1837633 and three other SNPs
(r2=0.97-0.99) shown in the Online Supplementary Figure
S3. These SNPs interact with the RB1CC1 gene promoter
(yellow line, P=10-11).
The recent GWAS on these three AL amyloidosis
cohorts reported four SNPs reaching (or almost reaching)
a genome-wide significance.2 With the exception of the
most significant SNP, rs9344, none of the other three
SNPs were specifically associated with the defined nine
clinical profiles. Interestingly, three completely new pro-
file-specific genetic loci were identified with homoge-
neous results from the three cohorts. Independent asso-
ciations of rs9344 with the two LCO profiles and of
rs10507419 with the two IgG profiles showed internal
consistency.     
The preferential association of rs9344 with LCO pro-
files could possibly be explained by the known associa-
tion of this SNP with translocation (11;14), the high
prevalence (58% of all cases) of this translocation in AL
amyloidosis and the resulting disturbance of IgH produc-
tion in AL amyloidosis and MM.2,6 However, no light
chain excess has been reported in either t(11;14) AL amy-
loidosis or in t(11;14) MM.7 Curiously, while the LCO
profiles were strongly associated with rs9344, the weak-
est association was noted for the IgG profile. Conversely,
rs10507419 was strongly associated with the IgG profiles
while weakly opposite associations were found with this
SNP and the LCO profiles. This dichotomy was further
supported by non-overlapping CIs for five SNPs among
the ten promising candidates identified for AL amyloido-
sis overall in the previous study (data shown in the Online
Supplementary Table S1).2 rs10507419 maps close to the
NBEA locus (13q13.3) which harbors a fragile site causing
deletion of the telomeric end of chromosome 13q in
patients with MM, monoclonal gammopathy of undeter-
mined significance (MGUS) and AL-amyloidosis.8 In pro-
moter capture Hi-C data we found that the rs10507419





Figure 2. Regional association plots showing the significant/top SNPs in the four AL amyloidosis clinical profiles. (A) l/k LCO profile; (B) IgG profile; C) heart
+ kidney profile; D) liver profile. The x-axis shows the chromosomal position as Mb and the mapped genes annotated from the University of California, Santa
Cruz (UCSC) genome browser. Genomic locations are given in the National Center for Biotechnology Information (NCBI) Build 37/UCSC hg19 coordinates. The y-
axis shows the significance (–log10 P; 2-tailed) on the left and recombination rates (light blue lines) on the right. The reference SNP is labeled and colored pur-
ple, the rest of the SNPs are colored based on their r2 to the reference SNP, on a shown scale, based on pairwise r2 values from HapMap CEU. Square-shaped
SNP symbols represent genotyped SNPs and circle-shaped SNPs represent imputed ones. In B) and D) second SNPs are also marked (rs61947292 and
rs1837633, respectively) as these are among the targets of the Hi-C experiments shown in the Online Supplementary Figures S2 and S3. Chr: chromosome. Ig:
immunoglobulin.
Liver profile SNP rs7820212 on chromosome 8q11.23
maps close to FAM150A, which encodes a ligand for
receptor tyrosine kinases, leukocyte tyrosine kinase
(LTK) and anaplastic lymphoma kinase (ALK). These
belong to the insulin receptor superfamily, and their aber-
rant activation has been described in many cancers, such
as non-small lung cancer and neuroblastoma in which
ALK mutations are common.9 Fusion genes of ALK are
often found in lymphomas with resulting downstream
activation of the Ras/Raf/MEK/ERK pathway.10
rs7820212 is adjacent to the RB1CC1 gene; Hi-C data
supported the fact that the rs7820212 locus interacts
with the RB1CC1 promoter.11 RB1CC1 has tumor sup-
pressor properties in enhancing RB1 gene expression in
cancer cells and promoting senescence.12 The SNP
changes the binding motif for CEBPB, which is an impor-
tant transcription factor regulating the expression of
genes involved in immune and inflammatory responses.13 
Limitations of the present work include the lack of
demonstrated functional data. However, some of the in
silico annotations gave promising functional clues, and
any functional genetics will be greatly facilitated by the
present kind of solid groundwork in patients. 
In conclusion, four SNPs reached genome-wide signifi-
cant associations in clinical profile-specific AL amyloido-
sis. The associations were different (with the exception
of rs9344) and generally stronger than those found for AL
amyloidosis in general, even though the sample size in
each profile was smaller than those for AL amyloidosis in
general.2 This may indicate that these particular profiles
are better able to define AL amyloidosis into molecular
subtypes which are more amenable to genetic analysis
and, possibly, therapeutic interventions. Particularly
striking were the distinct non-overlapping genetic associ-
ations for the LCO and IgG isotypes. The pathophysio-
logic basis of progression of MGUS into either MM or AL
amyloidosis has remained enigmatic, but the emerging
understanding of the genetic architecture of the three
plasma cell dyscrasias may start to provide answers to
the puzzle.14,15 
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